The value of detectable thyroglobulin in patients with differentiated thyroid cancer after initial 131I therapy

Clinical Endocrinology

Volumn 74, Issue 1, 2011, Pages 104-110

  Van Dijk, D ^a   Plukker, J T M ^a   Van Der Horst Schrivers, A N A ^a   Jansen, L ^a   Brouwers, A H ^a   Muller Kobold, A ^a   Sluiter, W J ^a   Links, T P ^a  

^a UNIVERSITY MEDICAL CENTER GRONINGEN   (Netherlands)

Author keywords

[No Author keywords available]

Indexed keywords

IODINE 131; THYROGLOBULIN; THYROGLOBULIN ANTIBODY;

ADULT; ARTICLE; CANCER MORTALITY; CANCER RADIOTHERAPY; CANCER RECURRENCE; CANCER SURVIVAL; CONTROLLED STUDY; DISEASE FREE SURVIVAL; FEMALE; FOLLOW UP; HISTOPATHOLOGY; HUMAN; HUMAN TISSUE; HURTLE THYROID CARCINOMA; LIFE EXPECTANCY; MAJOR CLINICAL STUDY; MALE; PRIORITY JOURNAL; PROGNOSIS; THYROGLOBULIN BLOOD LEVEL; THYROID CANCER; THYROID FOLLICULAR CARCINOMA; THYROID PAPILLARY CARCINOMA; WHOLE BODY SCINTISCANNING;

EID: 78650387894     PISSN: 03000664     EISSN: 13652265     Source Type: Journal    
DOI: 10.1111/j.1365-2265.2010.03885.x     Document Type: Article

References (17)

1. Cooper, D.S., Doherty, G.M., Haugen, B.R., et al. (2009) Revised American Thyroid Association management guidelines for patients with thyroid nodules and differentiated thyroid cancer. Thyroid, 19, 1167-1214.
2. Links, T.P., van Tol, K.M., Jager, P.L., et al. (2005) Life expectancy in differentiated thyroid cancer: a novel approach to survival analysis. Endocrine Related Cancer, 12, 273-280.
3. Mazzaferri, E.L., &, Kloos, R.T., (2001) Clinical review 128: Current approaches to primary therapy for papillary and follicular thyroid cancer. Journal of Clinical Endocrinology and Metabolism, 86, 1447-1463.
4. Tuttle, R.M., &, Leboeuf, R., (2008) Follow up approaches in thyroid cancer: a risk adapted paradigm. Endocrinology and Metabolism Clinics of North America, 37, 419-435. (Pubitemid 351698090)
5. Tuttle, R.M., Leboeuf, R., &, Martorella, A.J., (2007) Papillary thyroid cancer: monitoring and therapy. Endocrinology and Metabolism Clinics of North America, 36, 753-778.
6. Eustatia-Rutten, C.F., Corssmit, E.P., Biermasz, N.R., et al. (2006) Survival and death causes in differentiated thyroid carcinoma. Journal of Clinical Endocrinology and Metabolism, 91, 313-319.
7. Shaha, A., (2008) Selective surgical management of well-differentiated thyroid cancer. Annals of the New York Academy of Sciences, 1138, 58-64.
8. Phan, H.T., Jager, P.L., van der Wal, J.E., et al. (2008) The follow-up of patients with differentiated thyroid cancer and undetectable thyroglobulin (Tg) and Tg antibodies during ablation. European Journal of Endocrinology, 158, 77-83.
9. Haveman, J.W., Phan, H.T., Links, T.P., et al. (2005) Implications of mediastinal uptake of 131I with regard to surgery in patients with differentiated thyroid carcinoma. Cancer, 103, 59-67.
10. Persoon, A.C., Van Den Ouweland, J.M., Wilde, J., et al. (2006) Clinical utility of an automated immunochemiluminometric thyroglobulin assay in differentiated thyroid carcinoma. Clinical Chemistry, 52, 686-691.
11. Korn, E.L., Graubard, B.I., &, Midthune, D., (1997) Time-to-event analysis of longitudinal follow-up of a survey: choice of the time-scale. American Journal of Epidemiology, 145, 72-80.
12. Schlumberger, M., Hitzel, A., Toubert, M.E., et al. (2007) Comparison of seven serum thyroglobulin assays in the follow-up of papillary and follicular thyroid cancer patients. Journal of Clinical Endocrinology and Metabolism, 92, 2487-2495.
13. Spencer, C.A., (2004) Challenges of serum thyroglobulin (Tg) measurement in the presence of Tg autoantibodies. Journal of Clinical Endocrinology and Metabolism, 89, 3702-3704.
14. Spencer, C.A., Bergoglio, L.M., Kazarosyan, M., et al. (2005) Clinical impact of thyroglobulin (Tg) and Tg autoantibody method differences on the management of patients with differentiated thyroid carcinomas. Journal of Clinical Endocrinology and Metabolism, 90, 5566-5575.
15. Baudin, E., Do Cao, C., Cailleux, A.F., et al. (2003) Positive predictive value of serum thyroglobulin levels, measured during the first year of follow-up after thyroid hormone withdrawal, in thyroid cancer patients. Journal of Clinical Endocrinology and Metabolism, 88, 1107-1111.
16. Kloos, R.T., &, Mazzaferri, E.L., (2005) A single recombinant human thyrotropin-stimulated serum thyroglobulin measurement predicts differentiated thyroid carcinoma metastases three to five years later. Journal of Clinical Endocrinology and Metabolism, 90, 5047-5057.
17. Nikiforova, M.N., Tseng, G.C., Steward, D., et al. (2008) MicroRNA expression profiling of thyroid tumors: biological significance and diagnostic utility. Journal of Clinical Endocrinology and Metabolism, 93, 1600-1608.